KOSDAQBiotech & Pharma036480

Daesung Microbiological Labs

₩5,080▼ 1.17%2026-11-18 close
Market Cap
₩19.3B
Turnover
₩20,983,540
Volume
4.2K
Shares out.
3.8M
PER
—
PBR
0.6×
EPS
-₩293
Dividend Yield
1.44%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩75 per share · Prices as of the 2026-11-18 close

01

Report overview

Back in the Black Under a New Controlling Shareholder, Earnings Base Still Thin

Daesung Microbiological Labs returned to operating profit in 2025 and posted an operating profit again in the third quarter of 2026, but it still carries a net loss attributable to controlling shareholders over the last four quarters and changed its largest shareholder in March 2026.

  1. 1

    Revenue rose 9.2% to KRW 26 billion in 2025, and operating profit of KRW 714 million turned the business from loss to profit.

  2. 2

    Operating profit returned to the black in the third quarter of 2026 at KRW 83.65 million, while revenue fell 14.9% from a year earlier.

  3. 3

    The controlling-shareholder net loss for the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 1.11 billion.

  4. 4

    In March 2026 the largest shareholder changed to a private software developer that acquired a 38.6% stake for about KRW 16.1 billion.

  5. 5

    The value-up plan disclosed in April 2026 set targets for new product sales, overseas exports, R&D and cost competitiveness.

02

Business structure

Daesung Microbiological Labs was founded in 1966 as an animal-health drug maker and makes and sells more than 150 veterinary products, including preventive vaccines, antibiotics, antiparasitics and nutritional supplements.

It listed on KOSDAQ in April 2000, and its reporting is built around a single segment, veterinary medicines. In the 2024 business year, foot-and-mouth disease vaccines generated about KRW 4.5 billion, or 18.96% of sales, while the remaining product group contributed KRW 16.98 billion, or 71.35%.

The company says no single product accounts for more than roughly 5 to 10 percent of sales, which it presents as a spread-out mix. At the end of the third quarter of 2025, sales split into KRW 14.1 billion domestic (74%) and KRW 5 billion exports (26%), and the export share has been edging higher.

Distribution relies on about 200 domestic dealers and government procurement through the Public Procurement Service, while exports reach nine countries across Asia, Europe and other regions.

The production base was reinforced in 2022 through a factory expansion and KVGMP-grade facilities, which the company credits for overseas growth.

R&D runs through the Daesung Microbiological Research Institute, and the 2024 business report lists several vaccine projects, including an H9N2 avian influenza vaccine, at various development stages. The company points to its dealer network, KVGMP facilities and broad product line as its strengths.

The same report names only one competing product, Nobilis CAV P4, for a specific research project, so market-share comparisons with rivals are limited in the disclosures.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.2B₩600M8.2%
2025Q4₩6.9B-₩300M−3.9%
2026Q1₩5.1B-₩500M−10.1%
2026Q2₩6B-₩500M−7.9%
2026Q3₩6.1B₩83,653,6991.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩25.5B-₩300M₩1.7B−1.3%4.4%67.6%
2023₩25.6B-₩700M-₩700M−2.7%−1.8%72.1%
2024₩23.8B-₩1.6B-₩1.8B−6.5%−5.0%66.1%
2025₩26B₩700M₩600M2.7%1.7%63.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On the basis of the regular filings, annual revenue was KRW 25.5 billion in 2022, KRW 25.6 billion in 2023 (up 0.2% year on year), KRW 23.8 billion in 2024 (down 6.9% year on year) and KRW 26 billion in 2025 (up 9.2% year on year). 2025 was the largest year of the 2022 to 2025 span and 2024 the smallest.

Operating loss was KRW 328 million in 2022, KRW 689 million in 2023 (losses widened versus the prior year) and KRW 1.55 billion in 2024 (losses widened again), before operating profit of KRW 714 million in 2025 turned the result positive.

Operating margin moved from -1.3% in 2022 to -2.7% in 2023 and -6.5% in 2024, then recovered to 2.7% in 2025.

Profit attributable to controlling shareholders was KRW 1.7 billion in 2022, swung to a net loss of KRW 680 million in 2023, widened to a net loss of KRW 1.77 billion in 2024, and returned to a profit of KRW 598 million in 2025.

Net income including non-controlling interests follows the same direction but is a different figure. The company attributes the 2025 recovery to new export channels, including Cambodia, after exports weakened in 2024.

Quarterly, revenue peaked at KRW 7.18 billion in the third quarter of 2025 with operating profit of KRW 591 million, then slipped to KRW 6.92 billion in the fourth quarter (down 3.7% quarter on quarter) with an operating loss of KRW 270 million.

The first quarter of 2026 was the low point, with revenue of KRW 5.08 billion (down 26.5% quarter on quarter) and an operating loss of KRW 516 million that widened the loss.

Revenue then rose to KRW 6.01 billion in the second quarter (up 18.3%) with a narrower operating loss of KRW 472 million, and reached KRW 6.12 billion in the third quarter (up 1.7% quarter on quarter, down 14.9% year on year) with operating profit of KRW 83.65 million, a swing to profit that was still down 85.8% from a year earlier.

Revenue has grown for two consecutive quarters since the first quarter of 2026, yet the third-quarter figure remains below the 2025 third-quarter level. Net loss attributable to controlling shareholders over the last four quarters totals KRW 1.11 billion.

Equity at the end of 2025 was KRW 35.4 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 22.6 billion, and the debt ratio ran from 67.6% in 2022 to 72.1% in 2023, 66.1% in 2024 and 63.7% in 2025.

Operating cash flow was KRW 1.16 billion in 2022, KRW -1.23 billion in 2023, KRW 2.1 billion in 2024 and KRW 1.41 billion in 2025.

05

Industry analysis

Demand in this business depends on livestock disease control and the structure of animal production. According to a February 2026 report citing a market research firm, the global animal health market was about USD 4.33 billion in 2025.

In Korea, the confirmation of African swine fever on a pig farm in Gochang, Jeollabuk-do on February 2, 2026 lifted animal vaccine and antibiotic-related stocks intraday. Such outbreaks can lift short-term demand, but whether they translate into quarterly sales gains must be read from the filings.

Foot-and-mouth disease vaccines accounted for 18.96% of sales in the 2024 business year, showing that disease-response vaccines form one pillar of revenue. With 74% of sales domestic at the end of the third quarter of 2025, the company remains tied to domestic livestock conditions and government disease-control policy.

Exports at 26% reflect the push into Asian, South American and Middle Eastern markets, which the company describes as its growth route. The industry therefore combines short-term demand spikes from outbreaks with medium-term demand shaped by policy.

Competition appears to turn on the number of product approvals, dealer reach and the number of countries where products are registered. Listed peers such as Celltrion and Yuhan focus on human medicines, so direct comparisons of business structure are limited.

06

Outlook

In its value-up plan disclosed on April 20, 2026, the company set targets of expanding new product and domestic and overseas sales, exploring overseas export options and sustaining R&D.

Concrete steps include obtaining additional product approvals at home and abroad, developing new products through stronger R&D and improving cost competitiveness to widen operating margin. The company also said it would pay dividends based on stable net income growth.

The 2025 payout ratio was disclosed at 47.64%, and a cash dividend with a total payout of KRW 285 million was approved at the annual shareholders meeting on March 24, 2026.

Overseas trade-show activity continues, including participation in VIV Health and Nutrition Asia 2026 in Bangkok in March 2026 and a product showcase at a Seoul veterinary conference in late March 2026.

On management, the CEO transition took effect on March 24, 2026, when the two former representative directors resigned and Choi Seung-hoon became sole representative director; press reports said the new CEO highlighted AI-based R&D innovation. The disclosures do not give a specific timetable for new product approvals.

The next checkpoints are whether the 2026 operating margin exceeds the 2.7% recorded in 2025 and how the approvals and new product sales targeted in the value-up plan show up in reported results.

07

Valuation

PER
—
PBR
0.6×
ROE
-3.2%
EPS
-₩293
BPS
₩8,866
Dividend per share
₩75

Because the controlling-shareholder net loss has persisted over the last four quarters, a price-to-earnings ratio cannot be calculated on that basis. The price-to-book ratio sits below 1x, meaning the stock trades under the book value of its equity.

Equity of KRW 35.4 billion is entirely attributable to controlling shareholders, which makes the net-asset comparison relatively straightforward. Much of the asset base may be tied up in plants and other fixed assets, so book equity cannot be read directly as cash value.

The 2025 turn to profit has been followed by operating losses in the first and second quarters of 2026, so the earnings base remains short. A 2025 payout ratio of 47.64% was disclosed, and dividend size could move with earnings.

The March 2026 change in the largest shareholder and in the representative director leaves the governance shift as a variable in how valuation is read. Comparisons within animal health are possible, but comparisons of multiples with human-drug listed companies are limited by the difference in business structure.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Operating profit returned

Operating profit of KRW 714 million in 2025 turned the result positive, and KRW 83.65 million of operating profit in the third quarter of 2026 kept it there. Revenue has risen for two consecutive quarters since the low in the first quarter of 2026.

The margin recovery to 2.7% in 2025 runs in the same direction as the cost-competitiveness goal the company has set.

Export channels widening

At the end of the third quarter of 2025, exports reached KRW 5 billion, or 26% of sales. The company says it is widening exports through new channels such as Cambodia and through trade-show participation in South America and the Middle East. A rising export share would reduce dependence on domestic livestock conditions.

Shareholder return policy

A 2025 payout ratio of 47.64% was disclosed, and a cash dividend was approved at the shareholders meeting on March 24, 2026. The value-up plan states that dividends will be paid on the basis of steady net income growth. The fact that the policy is written into disclosures is a point in its favor on shareholder returns.

09

Bear factors

Thin earnings base

Operating losses ran from 2022 through 2024, and the 2025 profit was only KRW 714 million at the operating line. Operating losses in the first and second quarters of 2026 were followed by a profit in the third quarter alone.

Year-on-year revenue decline

Third-quarter 2026 revenue of KRW 6.12 billion fell 14.9% from a year earlier. Operating profit over the same comparison dropped 85.8%. After peaking in the third quarter of 2025 and bottoming in the first quarter of 2026, revenue is recovering but has not returned to the prior-year level.

Governance transition

The KRW 13.5 billion borrowing used to fund the March 2026 stake purchase is recorded as made by the acquirer, with collateral listed as the acquirer's site and building. Following the resignations of the two former representative directors, Choi Seung-hoon became sole representative director. How the new management direction appears in future disclosures is the next point to watch.

10

Risk factors

Outbreak-driven demand timing

Livestock disease outbreaks can lift vaccine and antibiotic demand, but the effect varies with location and scale. The share price swung sharply intraday on the February 2026 African swine fever report, which shows sensitivity to headlines. There can be a lag between headlines and revenue recognition.

Durability of margin recovery

The 2.7% operating margin in 2025 moved the company out of the 2022 to 2024 loss years, but the cushion is thin. The swing from an operating loss in the second quarter of 2026 to a profit in the third shows how volatile quarterly results remain. Whether cost gains and new product sales convert into lasting profit is the key question.

Borrowing and balance sheet

Total liabilities were KRW 22.6 billion, and the debt ratio at the end of 2025 was 63.7%. Operating cash flow was KRW 1.41 billion in 2025 but was KRW -1.23 billion in 2023.

The acquisition borrowing is recorded under the acquirer's name, and any effect of that financing structure on the company's direction has not yet appeared in disclosures.

11

What to watch next

  1. Late March 2027 (annual report deadline for the 2026 business year)

    Revenue, operating profit and profit attributable to controlling shareholders for the 2026 business year will be fixed in the annual report. The comparison points are the margin change from 2.7% in 2025 and how much the last four quarters' net loss narrows on a full-year basis.

  2. 2027 annual shareholders meeting (date not yet set, usually in March)

    The 2026 dividend decision and progress on the value-up plan will appear together in the meeting results and the annual report. It will show whether dividend size moves in line with the earnings recovery.

  3. Around May 15, 2027 (deadline for the first-quarter 2027 report)

    Whether first-quarter 2027 revenue rises from the first-quarter 2026 low of KRW 5.08 billion, and whether operating profit stays positive, are the points to check.

  4. End of December 2026 (end of the fourth quarter of 2026)

    Whether the third-quarter 2026 profit carries into the fourth quarter is the benchmark. Fourth-quarter 2026 results will be confirmed through disclosures in early 2027.

  5. During 2027 (timing not set)

    Whether additional domestic and overseas product approvals are obtained is a core milestone in the value-up plan. Approval timing will be disclosed, and the link to new product sales will be tracked alongside it.

12

Overall view

Daesung Microbiological Labs returned to operating profit in 2025 at KRW 714 million and posted an operating profit of KRW 83.65 million again in the third quarter of 2026.

Over the same third quarter, however, revenue fell 14.9% from a year earlier, and the controlling-shareholder net loss for the last four quarters totals KRW 1.11 billion.

Because the third-quarter profit followed operating losses in the first and second quarters of 2026, the durability of the turnaround can so far be checked only over a few quarters.

The business centers on more than 150 veterinary products, with a 74% domestic and 26% export mix, and the export share has been edging higher.

The March 2026 change in the largest shareholder and the start of the Choi Seung-hoon management period came alongside a value-up plan in April 2026 that names new products, exports, R&D and cost competitiveness as priorities.

Outbreak-driven demand expectations and a thin earnings base are both variables in how the share price is read. On valuation, the price-to-book ratio sits below 1x, while a price-to-earnings ratio cannot be calculated given the short earnings base.

The next checkpoints are operating profit in the 2026 annual report, due by March 2027, and first-quarter 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jobkorea.co.kr
  2. comp.fnguide.com
  3. m.jobkorea.co.kr
  4. news.nate.com
  5. news.nate.com
  6. news.nate.com
  7. sujuradar.com
  8. kind.krx.co.kr
  9. edaily.co.kr
  10. saramin.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. dsmbio.com
  16. ajunews.com
  17. m.news.nate.com
  18. joongangenews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis